Values as of: 2025-05-20
COMMON STOCK | Medical Instruments & Supplies | OTC Pink
Last Closing
USD 19.64Change
-0.26 (-1.31)%Market Cap
USD 12.70BVolume
2.60KVerdict
Verdict
Terumo Corp is a manufacturer and supplier of pharmaceuticals and medical tools and equipment. Its products include health foods, transfusion and infusion equipment, disposable medical supply, clinical testing systems & artificial organs.
Company Website : http://www.terumo.co.jp
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| ESLOY | Essilor International SA |
+1.54 (+1.05%) |
USD 126.80B |
| ESLOF | EssilorLuxottica Société ano.. |
-5.00 (-1.69%) |
USD 125.52B |
| HOCPF | HOYA Corporation |
+6.61 (+5.42%) |
USD 43.54B |
| HOCPY | Hoya Corp |
+0.52 (+0.43%) |
USD 41.79B |
| SDMHF | Sartorius Stedim Biotech S.A |
+2.32 (+1.05%) |
USD 22.03B |
| SRTOY | Sartorius Stedim Biotech S.A |
N/A |
USD 21.84B |
| CLPBY | Coloplast A |
-0.08 (-0.83%) |
USD 21.79B |
| CLPBF | Coloplast A/S |
N/A |
USD 21.70B |
| SAUHF | Straumann Holding AG |
-2.99 (-2.29%) |
USD 20.49B |
| SUVPF | Sartorius Aktiengesellschaft |
N/A |
USD 16.40B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| DXJH | 0.00 % | 0.48 % |
N/A |
N/A | |
| CNKY:LSE | iShares VII PLC - iShares.. | 0.00 % | 0.00 % |
-133.00 (-0.93%) |
USD 50.24B |
| XDJP:LSE | Xtrackers Nikkei 225 UCIT.. | 0.00 % | 0.00 % |
-13.25 (-0.93%) |
N/A |
| SXRZ:F | iShares VII PLC - iShares.. | 0.00 % | 0.00 % |
+1.55 (+-0.93%) |
USD 52.44B |
| EXX7:XETRA | iShares Nikkei 225 UCITS .. | 0.00 % | 0.00 % |
-0.05 (-0.93%) |
USD 28.25B |
| SXRZ:XETRA | iShares VII PLC - iShares.. | 0.00 % | 0.00 % |
-0.65 (-0.93%) |
N/A |
| XDJE:XETRA | Xtrackers Nikkei 225 UCIT.. | 0.00 % | 0.00 % |
-0.30 (-0.93%) |
N/A |
| XDJP:XETRA | Xtrackers Nikkei 225 UCIT.. | 0.00 % | 0.00 % |
-0.05 (-0.93%) |
N/A |
| 1329:TSE | iShares Core Nikkei 225 E.. | 0.00 % | 0.00 % |
-36.00 (-0.93%) |
USD 1,529.93B |
| 1330:TSE | Nikko Nikkei 225 Listed | 0.00 % | 0.00 % |
-380.00 (-0.93%) |
USD 5,423.56B |
| 1369:TSE | DIAM Nikkei 225 | 0.00 % | 0.00 % |
-510.00 (-0.93%) |
USD 451.27B |
| 1578:TSE | Listed Index Fund Nikkei .. | 0.00 % | 0.00 % |
-24.00 (-0.93%) |
USD 12.13B |
| 1397:TSE | SMDS SMDAM NIKKEI225 ETF | 0.00 % | 0.00 % |
-350.00 (-0.93%) |
USD 195.63B |
| Market Performance vs. Industry/Classification (Medical Instruments & Supplies) | Market Performance vs. Exchange (OTC Pink) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 2.45% | 53% | F | 50% | F | ||
| Dividend Return | 0.22% | 13% | F | 2% | F | ||
| Total Return | 2.67% | 52% | F | 50% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 15.53% | 76% | C+ | 70% | C- | ||
| Dividend Return | 1.31% | 53% | F | 16% | F | ||
| Total Return | 16.84% | 72% | C | 69% | C- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 13.86% | 70% | C- | 60% | D- | ||
| Dividend Return | 5.42% | 35% | F | 11% | F | ||
| Total Return | 19.27% | 70% | C- | 56% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | -2.00% | 51% | F | 38% | F | ||
| Dividend Return | 34.61% | 84% | B | 74% | C | ||
| Total Return | 36.61% | 100% | F | 95% | A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 53.11% | 38% | F | 46% | F | ||
| Risk Adjusted Return | 65.17% | 97% | N/A | 91% | A- | ||
| Market Capitalization | 12.70B | 92% | A | 96% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
